Text Size

Effect of Donepezil on the Reorganization of Cognitive Neural Network in Patients With Post-Stroke Cognitive Impairment

The recruitment status of this study is unknown because the information has not been verified recently.
Verified July 2007 by Samsung Medical Center.
Recruitment status was  Recruiting
Sponsor:
Information provided by:
Samsung Medical Center
ClinicalTrials.gov Identifier:
NCT00530478
First received: September 13, 2007
Last updated: NA
Last verified: July 2007
History: No changes posted
  Purpose

The purpose of this study is to demonstrate the efficacy and safety of donepezil on the recovery of cognitive function in patients with stroke and to delineate the neurophysiologic mechanisms of the therapeutic effect of donepezil on the recovery of cognitive network using functional neuroimaging technique.


Condition Intervention
Stroke
 Drug: Donepezil

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Samsung Medical Center:

  Eligibility

Ages Eligible for Study:   16 Years to 80 Years
Genders Eligible for Study:   Both
Criteria

Inclusion Criteria:

  • Ischemic stroke in the territory of right or left middle cerebral artery
  • Post-onset duration of the recent-onset stroke is over 3 months
  • Cognitive deficit ranged from 10 to 26 by minimal mental status examination (MMSE) score
  • Disturbance in activities of daily living (ADL) ranged 0.5 ~ 2.0 by clinical dementia rating (CDR) scale

Exclusion Criteria:

  • Severe internal carotid artery stenosis on the lesion side
  • Cardiac pacemaker or intracranial metal insertion
  • Post-stroke seizure disorder or any evidence of epileptic spikes on electroencephalography (EEG)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00530478

Contacts
Contact: Yun-Hee Kim, MD, PHD 82-2-3410-2818 yunkim@smc.samsung.co.kr

Locations
Korea, Republic of
Samsung Medical Center Recruiting
Seoul, Korea, Republic of, 135-710
Contact: Yun-Hee Kim, MD, PHD     82-2-3410-2818     yunkim@smc.samsung.co.kr    
Sponsors and Collaborators
Samsung Medical Center
Investigators
Principal Investigator: Suk Hoon Ohn, MD, MS Samsung Medical Center
Principal Investigator: Yun Hee Park, MD Samsung Medical Center
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00530478     History of Changes
Other Study ID Numbers: 2006-04-023
Study First Received: September 13, 2007
Last Updated: September 13, 2007
Health Authority: South Korea: Institutional Review Board
South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by Samsung Medical Center:
Donepezil
Stroke
Cognitive function
Cognitive neural network

Additional relevant MeSH terms:
Stroke
Cerebral Infarction
Cerebrovascular Disorders
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Vascular Diseases
Cardiovascular Diseases
Brain Infarction
Brain Ischemia
Donepezil
 Cholinesterase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Cholinergic Agents
Neurotransmitter Agents
Physiological Effects of Drugs
Nootropic Agents
Central Nervous System Agents
Therapeutic Uses

ClinicalTrials.gov processed this record on May 21, 2013